Evidence map›Paper›PMID 31930767›Full record

ArticleMolecular oncology2020

Downregulation of circulating miR 802-5p and miR 194-5p and upregulation of brain MEF2C along breast cancer brain metastasization.

Marta Sereno, János Haskó, Kinga Molnár, Sarah J Medina, Zita Reisz, Rui Malhó, Mafalda Videira, László Tiszlavicz, Stephanie A Booth, Imola Wilhelm and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Marta SerenoFaculdade de Farmácia, Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, Portugal.
János HaskóInstitute of Biophysics, Biological Research Centre, Szeged, Hungary.
Kinga MolnárInstitute of Biophysics, Biological Research Centre, Szeged, Hungary.
Sarah J MedinaPrion Diseases Section, Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, MB, Canada.
Zita ReiszDepartment of Pathology, University of Szeged, Hungary.
Rui MalhóFaculdade de Ciências, BioISI, Instituto de Biossistemas e Ciências Integrativas, Universidade de Lisboa, Portugal.
Mafalda VideiraFaculdade de Farmácia, Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, Portugal.
László TiszlaviczDepartment of Pathology, University of Szeged, Hungary.
Stephanie A BoothPrion Diseases Section, Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, MB, Canada.
Imola WilhelmInstitute of Biophysics, Biological Research Centre, Szeged, Hungary.ORCID 0000-0003-2366-7337
István A KrizbaiInstitute of Biophysics, Biological Research Centre, Szeged, Hungary.ORCID 0000-0002-0764-1527
Maria Alexandra BritoFaculdade de Farmácia, Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, Portugal.ORCID 0000-0002-8493-4649
HUN-REN Szegedi Biológiai Kutatóközpont · HUUniversity of Lisbon · PTUniversity of Szeged · HUManitoba Health · CAPublic Health Agency of Canada · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer brain metastases (BCBMs) have been underinvestigated despite their high incidence and poor outcome. MicroRNAs (miRNAs), and particularly circulating miRNAs, regulate multiple cellular functions, and their deregulation has been reported in different types of cancer and metastasis. However, their signature in plasma along brain metastasis development and their relevant targets remain undetermined. Here, we used a mouse model of BCBM and next-generation sequencing (NGS) to establish the alterations in circulating miRNAs during brain metastasis formation and development. We further performed bioinformatics analysis to identify their targets with relevance in the metastatic process. We additionally analyzed human resected brain metastasis samples of breast cancer patients for target expression validation. Breast cancer cells were injected in the carotid artery of mice to preferentially induce metastasis in the brain, and samples were collected at different timepoints (5 h, 3, 7, and 10 days) to follow metastasis development in the brain and in peripheral organs. Metastases were detected from 7 days onwards, mainly in the brain. NGS revealed a deregulation of circulating miRNA profile during BCBM progression, rising from 18% at 3 days to 30% at 10 days following malignant cells' injection. Work was focused on those altered prior to metastasis detection, among which were miR-802-5p and miR-194-5p, whose downregulation was validated by qPCR. Using targetscan and diana tools, the transcription factor myocyte enhancer factor 2C (MEF2C) was identified as a target for both miRNAs, and its expression was increasingly observed in malignant cells along brain metastasis development. Its upregulation was also observed in peritumoral astrocytes pointing to a role of MEF2C in the crosstalk between tumor cells and astrocytes. MEF2C expression was also observed in human BCBM, validating the observation in mouse. Collectively, downregulation of circulating miR-802-5p and miR-194-5p appears as a precocious event in BCBM and MEF2C emerges as a new player in brain metastasis development.

Indexed as

AnimalsAstrocytesBiomarkers, TumorBrain NeoplasmsBreast NeoplasmsCell Line, TumorComputational BiologyDisease ProgressionDown-RegulationFemaleGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansMammary Neoplasms, AnimalMEF2 Transcription FactorsMiceBiomarkers, TumorMef2c protein, mouseMEF2 Transcription FactorsMicroRNAsMIRN194 microRNA, mouseMIRN802 microRNA, mousebioinformaticsbrain metastasisbreast cancermicroRNAsmyocyte enhancer factor 2Cnext-generation sequencing

Identifiers

PMID31930767
PMCPMC7053247
OpenAlexW3000218303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.